Global Schizophrenia Therapeutics Report 2017 - Pipeline Review of 73 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Schizophrenia - Pipeline Review, H1 2017" report to their offering.

Schizophrenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Schizophrenia - Overview
  3. Schizophrenia - Therapeutics Development
  4. Schizophrenia - Therapeutics Assessment
  5. Schizophrenia - Companies Involved in Therapeutics Development
  6. Schizophrenia - Drug Profiles
  7. Schizophrenia - Dormant Projects
  8. Schizophrenia - Discontinued Products
  9. Schizophrenia - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Acadia Pharmaceuticals Inc
  • Adamed Sp z oo
  • Aequus Pharmaceuticals Inc
  • AgeneBio Inc
  • Alkermes Plc
  • Angita BV
  • Astellas Pharma Inc
  • Athersys Inc
  • Avanir Pharmaceuticals Inc
  • Avineuro Pharmaceuticals Inc
  • BCWorld Pharm Co Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GeNeuro SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GP Pharm SA
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • JT Pharmaceuticals Inc
  • Karuna Pharmaceuticals Inc
  • Lohocla Research Corp
  • Luye Pharma Group Ltd
  • Mapi Pharma Ltd
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Pfizer Inc
  • Promentis Pharmaceuticals Inc
  • Ra Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Sage Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • VLP Therapeutics LLC

For more information about this report visit http://www.researchandmarkets.com/research/kwtxc9/schizophrenia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Schizophrenia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Schizophrenia Drugs